Kornimate/medical-research-clean huggingface dataset:
total-body fdg pet for radiotherapy response assessment in head and neck cancer

Conditions: Head and Neck Cancer

Summary: the overall goal of this research study is to understand how 18f-fluorodeoxyglucose (fdg), a radioactive sugar behaves in head and neck cancer (hnc) and inflammation immediately following injection and at many hours post-injection, with the world's first total-body positron emission tomography (pet)/computed tomography (ct) scanner (explorer).


Eligibility criteria:
inclusion criteria: 1. stage ii-iva (american joint committee on cancer, 8th edition) oc who are planned for rt (≥60 gy) as per routine clinical standard. 2. patient must be ≥18 years of age. 3. willing and able to lay motionless in a supine position for up to 60 minutes 4. patient must be able to provide study specific informed consent prior to study entry. 5. patient must be able to adhere to the study visit schedule and other protocol requirements (including prolonged fasting). exclusion criteria: 1. prior rt for any malignancy leading to overlap with planned rt fields. 2. prior chemotherapy for any malignancy. 3. subjects suffering from severe claustrophobia. 4. subjects who have had a research study involving radiation within one year of enrolling in this study 5. subjects who are pregnant (subjects 18 to 60 years old who are able to become pregnant unless documented hysterectomy or bilateral ovarian removal is available will be tested prior to injection of imaging agent - positive test will exclude from participating in the study) 6. subjects who are breastfeeding 7. prisoners. 8. any significant medical condition that in the opinion of the investigator would prevent the subject from participating and/or adhering to study related procedures or interfere with subject safety (e.g., poorly controlled diabetes). 9. children (\<18 years of age). 10. body weight more than 240 kg (529 pounds) -
acute dietary nitrate in dilated cardiomyopathy

Conditions: Cardiomyopathy

Summary: acute consumption of dietary nitrate (as beetroot juice) has been shown to improve exercise capacity in athletes, healthy adults and subjects with both peripheral vascular disease or copd. many patients with dilated cardiomyopathy have reduced exercise capacity, the investigators hypothesized that acute nitrate consumption might increase incremental shuttle walk test (iswt) distance in dilated cardiomyopathy subjects compared to a placebo beetroot juice.

acute consumption of dietary nitrate (as beetroot juice) has been shown to improve exercise capacity in athletes, healthy adults and subjects with both peripheral vascular disease or copd. many patients with dilated cardiomyopathy have reduced exercise capacity, the investigators hypothesized that acute nitrate consumption might increase incremental shuttle walk test (iswt) distance in dilated cardiomyopathy subjects compared to a placebo beetroot juice. this study is a randomized, double-blind placebo-controlled, crossover trial. resting blood pressure, phlebotomy and iswt will be performed. following completion, each subject is randomized to consume beetroot juice or placebo. 3 hours later, the same assessments are repeated by the same people. after a 7d washout, the entire protocol is repeated with the crossover beverage.

Eligibility criteria:
inclusion criteria: * clinically stable, * confirmed non-ischemic, dilated cardiomyopathy exclusion criteria: * active musculo-skeletal conditions * ischemic heart disease * pulmonary hypertension * copd * taking vasodilators * diabetes mellitus
respiratory outcome of children from the feped cohort

Conditions: Asthma in Children

Summary: early lung function deficits represent a significant risk factor for the evolution toward chronic obstructive pulmonary disease later in life. prematurity and in utero tobacco smoke exposure are already known to predispose children to develop a non-reversible obstructive ventilatory defect in adulthood. the role of vitamin d status during pregnancy is less certain. in humans, low vitamin d concentrations during pregnancy are associated to an increased risk of asthma in children. in murine models, low vitamin d concentrations during pregnancy are associated to structural abnormalities of the airways in mouse pups. investigators hypothesized that vitamin d play a role in early airways development, from the first trimester of pregnancy. to bring arguments to this hypothesis, the investigators will study the association of airway resistance in children aged 5 to 6 years old with the concentration of vitamin d during the first trimester of pregnancy in their mothers.

children aged 5 to 6 years old will be included from the feped cohort. the feped cohort is a cohort of french pregnant women designed to study the association between vitamin d status during pregnancy and the risk of pre-eclampsia. vitamin d concentration at first and third trimester of pregnancy as well as in cord blood is available for 1400 women. investigators will include 200 children born from these women. children will undergo lung function tests and prick-tests and parents will answer the isaac questionnaire that is a standardised questionnaire designed to evaluate asthma and rhinitis symptoms. the main outcome of this study will be specific airway resistance. the investigators will look for an association between specific airway resistance and vitamin d concentration measured during the first trimester of pregnancy in their mothers.

Eligibility criteria:
inclusion criteria: * term-born child (gestational age ≥ 37 weeks of post-menstrual age) whose mother was included in the feped cohort * measure of vitamin d concentration available at the first and third trimester of pregnancy and in cord blood * cord blood sample available for dna extraction * child's age between 5 and 6 years old at the time of participation * written informed consent obtained from the legal guardian of the child * health insurance exclusion criteria: * parent's' refusal * underlying disease that does not allow the performance of lung function tests

Keywords: lung function children vitamin d copd
a soft robotics approach towards finger joint deformities in rheumatic diseases

Conditions: Osteoarthritis

Summary: the study is to investigate the effect of a soft robotic glove approach providing continuous passive motion of fingers (flexion and extension) on degenerative arthritis patients. the approach may help reduce pain, maintain mobility and flexibility and to improve hand function.

the aim is to investigate the effect of soft robotic gloves in providing continuous passive motion of the fingers (finger flexion and extension) of degenerative arthritis patients, for the purpose of providing pain relief and alleviating stiffness at the finger joints. specifically, we intend to 1) observe the changes in range of motion of the fingers using the total active motion (tam) measure; 2) observe the changes in grip strength and pinch strength; and 3) record changes in the patients' perception of performance in activities of daily living using the canadian occupational performance measure (copm). the hypothesis is that a soft robotics approach in providing continuous passive motion of the finger joints of degenerative arthritis patients can reduce pain, maintain mobility and flexibility of the joints, and to improve hand function. the soft robotics approach and the standard hand therapy is better than the standard hand therapy alone. the proposed soft robotic glove is capable of providing continuous passive motion (flexion and extension) of the fingers, and in addition, it is also designed to be portable and easy to operate, with minimal supervision. it is aimed at the home therapy of degenerative arthritis patients. in this study, by using the soft robotic glove and in observing changes in finger range of motion, grip and pinch strength, as well as perception of performance in daily activities. this is important in establishing this device as a viable means to ultimately slow down the progression of degenerative arthritis, and to significantly improve the patients' abilities in carrying out activities of daily living, which had been impaired by degenerative arthritis.

Eligibility criteria:
inclusion criteria: 1. aged 30-90 years regardless of race 2. osteoarthritis of the hand (consistent with acr criteria 1990) 3. ability to pay attention and maintain supported sitting for 45 mins continuously 4. able to give own consent 5. able to comprehend and follow commands (abbreviated mental test \>= 7) exclusion criteria: 1. inflammatory arthritis (e.g. rheumatoid arthritis), trigger fingers, carpal tunnel syndrome (by symptoms), finger contractures 2. recent steroid injections in the wrist/hand joints within the past 3 months 3. anti-inflammatory drugs (e.g. non-steroidal anti-inflammatory drugs or oral steroid) in the past 1 month 4. old stroke and/or spasticity affecting the upper limbs 5. epilepsy for the last 6 months as of the date of recruitment 6. poor skin conditions which would hamper donning robotic gloves 7. pregnancy

Keywords: degenerative arthritis, rheumatic diseases
immersive virtual reality & obsessive compulsive disorder

Conditions: Obsessive-Compulsive Disorder

Summary: immersive vr (ivr) is based on the generation and projection of images from different perspectives. obsessive compulsive disorder (ocd) is considered one of the 5 most common mental disorders and one of the 20 most disabling diseases according to the world health organization (who). its vital prevalence is about 2.5%. this study aims to establish the effectiveness of a cognitive-behavioral intervention - individual and group - using ivr in patients diagnosed with ocd compared to a group receiving standard treatment by the mental health center. a sample will be obtained from the list of all patients registered in the mental health service of the university hospital of vic (vic, catalonia) with the primary or secondary diagnosis of obsessive compulsive disorder according to diagnostic and statistical manual of mental disorders (dsm 5) and in active treatment status in the period between january 2021 and january 2023. randomized controlled clinical trial. variables: sociodemographic, clinical, ocd symptom follow-up and quality of life. measurement instruments: yale-brown obsessive compulsive scale (y-bocs), state-trait anxiety inventory (stai), beck depression inventory (bdi), immersive tendencies questionnaire (itq), presence questionnaire, euroqol-5d (eq-5d). inclusion criteria: patients over 18 years of age with a primary or secondary diagnosis of obsessive compulsive disorder with one of the following specifiers: with good or acceptable introspection (1) or with little introspection (2); persons with current activity at the mental health center. exclusion criteria: patients with a diagnosis of intellectual disability, autistic spectrum disorder, active substance-related disorders, neuro-cognitive disorder and/or severe personality disorder; acute psychopathological decompensation; insufficient command of catalan and/or spanish; advanced disease and/or disease that significantly hinders the follow-up of the intervention.


Eligibility criteria:
inclusion criteria: * adults (≥18 years of age) * outpatient * current diagnostic of obsessive compulsive disorder with good or fair insight (1) or with poor insight (2) * follow-up by mental health network in vic hospital consortium of catalonia * signed informed consent exclusion criteria: * intellectual disabilities * autism spectrum disorder * active substance-related disorders * neurocognitive disorders * several personality disorders * clinical acute psychotic relapse

Keywords: obsessive-compulsive disorder immersive virtual reality psychological treatment
protocol for postmenopausal women at increased risk of developing breast cancer

Conditions: Breast Cancer

Summary: a study to examine the potential associations between common single nucleotide polymorphisms and pre-cancerous conditions in breast tissue specimens from postmenopausal women.

a study to examine the correlation between single nucleotide polymorphisms (snps) affecting steroid and carcinogen metabolism and benign breast tissue cytomorphology collected via random periareolar fine needle aspiration in postmenopausal women at increased risk for breast cancer and taking hormone replacement therapy.

Eligibility criteria:
inclusion criteria: * postmenopausal women on or off hormone replacement therapy * at high risk of developing breast cancer determined by family or personal history * postmenopausal women not on hormone replacement therapy for at minimum six months prior to corresponding aspiration * willing to participate in companion protocol (kumc hsc#4601) for random periareolar fine needle aspiration (rpfna) for correlational studies exclusion criteria: * women who have been on raloxifene, tamoxifen, letrozole, anastrozole or exemestane within the six months prior to rpfna.

Keywords: snps single nucleotide polymorphism breast atypia breast epithelial hyperplasia high risk for breast cancer
a study of aln-hsd in healthy adult subjects and adult patients with nonalcoholic steatohepatitis (nash)

Conditions: Nonalcoholic Steatohepatitis; NASH

Summary: the purpose of this study is to evaluate the safety and tolerability of single ascending doses of aln-hsd in healthy participants (part a) and multiple doses of aln-hsd in patients with nash (parts b and c).


Eligibility criteria:
inclusion criteria: * part a only * has body mass index (bmi) ≥18 kg/m\^2 and ≤28 kg/m\^2 * has normal 12-lead electrocardiogram (ecg) * parts b and c only: * has bmi ≥18 kg/m\^2 and ≤40 kg/m\^2 * has a diagnosis of nash documented in the patient's medical history or a clinical suspicion of nash based on defined study criteria * has screening liver biopsy with nash activity score (nas) score of ≥3 per nash clinical research network (crn) criteria exclusion criteria: * parts a, b and c: * has any clinical safety laboratory result considered clinically significant and unacceptable by the investigator * has known active human immunodeficiency virus (hiv), hepatitis b virus (hbv), or hepatitis c virus (hcv) infection * has known history or evidence of drug abuse, within 12 months prior to screening * has evidence of other forms of known chronic liver disease * has recently received an investigational agent * has any uncontrolled or serious disease, medical or surgical condition that my interfere with participation or data interpretation * has excessive alcohol intake for ≥ 3 months during past year * has history of intolerance to sc injection(s) * has international normalized ratio (inr) \>1.2 * has platelet count \<140x10\^9/l * part a only * has systolic blood pressure (bp) \>140 mmhg and diastolic \>90 mmhg; * has used certain prescription drugs within last 14 days prior to screening * has used certain over the counter (otc) medication within 7 days prior to screening * has estimated glomerular filtration rate (gfr) \<90 ml/min/1.73m\^2 at screening * parts b and c only * has abnormal ecg * has changes in certain prescription medications defined in the protocol within the specified timeframe prior to screening * has gfr\<45ml/min/1.73m\^2

Keywords: hepatobiliary disorders non-alcoholic fatty liver disease nafld fatty liver rnai therapeutic
biomarker study of blood samples from patients with non-small cell lung cancer treated with carboplatin and paclitaxel with or without bevacizumab

Conditions: Lung Cancer

Summary: rationale: studying samples of blood in the laboratory from patients undergoing treatment for non-small cell lung cancer may help doctors predict how patients will respond to treatment. purpose: this laboratory study is looking at proteomic patterns in stored blood samples from patients undergoing treatment for non-small cell lung cancer.

objectives: primary * to develop a serum proteomic classifier using matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry analysis of blood samples from patients with non-squamous cell non-small cell lung cancer to predict benefit, in terms of survival and time to progression, from treatment with bevacizumab in combination with carboplatin and paclitaxel. secondary * to better quantitate candidate biomarkers by using more advanced mass spectrometric technologies, including multiple-reaction monitoring and heavy-labeled peptides. outline: previously collected pre-treatment samples of serum or plasma are randomly selected from patients enrolled on protocol ecog-4599 (i.e., 60 from the bevacizumab arm and 30 from the control arm). samples are analyzed by matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry to identify patterns from protein spectra that correlate with patient survival.

Eligibility criteria:
disease characteristics: * available serum and plasma samples from patients with previously untreated locally advanced, metastatic, or recurrent non-squamous cell non-small cell lung cancer * enrolled on clinical trial ecog-4599 * treated with carboplatin and paclitaxel with or without bevacizumab patient characteristics: * not specified prior concurrent therapy: * see disease characteristics

Keywords: stage iiib non-small cell lung cancer recurrent non-small cell lung cancer stage iv non-small cell lung cancer adenocarcinoma of the lung bronchoalveolar cell lung cancer
treatment of renal sarcoidosis by methylprednisolone bolus

Conditions: Renal Sarcoidosis

Summary: renal sarcoidosis treatment is based on steroids, but the dose and duration are unknown. despite this treatment, most patients will have chronic kidney disease. from our previous studies, the investigators believe that high dose steroids by methylprednisolone bolus will improve patient outcome and renal function.

in a multicentric, randomized, open trial, the investigators will assess the efficacy of methylprednisolone bolus at 15mg/kg/d for 3 days before oral steroids on renal function improvement in renal sarcoidosis patients.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * acute kidney injury with estimated glomerular filtration rate (egfr) \ 25% or an increase of \> 30 µmol/l, since at least 3 months. * sarcoidosis diagnostic criteria according to ats/ers/wasog (am j respir crit care med 1999) * renal biopsy compatible with renal sarcoidosis : * granulomatosis tubulo-interstitial nephropathy and extra-renal damage of histologically proved or suggestive sarcoidosis or * tubulo-interstitial nephropathy without granuloma and extra-renal damage of histologically proved sarcoidosis * informed consent * patients with social security exclusion criteria: * corticosteroids greater than 0,25 mg/kg/j prednisone equivalent * introduction of an immunosuppressant in the month before inclusion * another cause of renal granulomatosis or tubulo-interstitial nephropathy * isolated renal damage without extra-renal past or present damage for a sarcoidosis * chronic renal failure, prior sarcoidosis with egfr \< 30 ml/min/1,73 m2 * acute renal failure from other causes. if hypercalcaemia is greater than 3 mmol/l, the correction of any dehydration will systematically salt intake, followed of renal function control before inclusion. * pregnancy, nursing * tuberculosis * uncontrolled sepsis * uncontrolled psychotic state * hypersensibility to methylprednisolone hemisuccinate * drugs prescription causing wave burst arrhythmia and/or long qt on ecg

Keywords: methylprednisolone prednisone renal sarcoidosis treatment
systemic inflammatory indices as a non-invasive grading modality for endometriosis

Conditions: Endometriosis

Summary: endometriosis (ems) is one of the commonest chronic inflammatory disorder affecting women and is characterized by the presence and growth of endometrial-like glandular epithelial and stromal cells outside the uterus leading to multiple clinical symptoms affecting patients quality of life and fertility with high recurrence rate . the systemic immune inflammatory index (sii) and systemic inflammatory response index (siri) are documented as prognostic serum biomarker in many kinds of cancer and for the need and outcomes of adjuvant therapies for various cancers .


Eligibility criteria:
inclusion criteria: * women with clinical manifestations suggestive of having em; * women who was professionally diagnosed; * women who was diagnosed by radiologic workup; * women were free of exclusion criteria. exclusion criteria: * women with em and were maintained on treatment or underwent operative interference during the last three months; * patients had autoimmune diseases, maintained on immunosuppressive therapy for any indication; * women with cancer elsewhere in the body or receiving adjuvant therapies for cancer; * patients receiving therapies for viral disorders especially covid; * patients refusing to undergo the exploratory laparoscopy.
system accuracy evaluation of 2 ce-marked blood glucose monitoring system

Conditions: Diabetes

Summary: the objective of this study is the evaluation of system accuracy following iso 15197:2013 (e), clause 6.3 in which accuracy requirements and applicable test procedures for blood glucose monitoring systems intended for self-monitoring of blood glucose by patients are stipulated. however in this study, system accuracy evaluation will be performed for hemocue glucose 201+ and hemocue glucose 201 rt which are both glucose monitoring systems for professional use only on behalf of the idt with one reagent system lot for each bgms. main goal is the evaluation of system accuracy of both of the hemocue systems. (english)


Eligibility criteria:
inclusion criteria: * male or female, with type 1 diabetes, type 2 diabetes or subjects without diabetes * signed informed consent form * minimum age of 18 years * subjects are legally competent and capable to understand character, meaning and consequences of the study. * if blood glucose values \ 300 mg/dl shall be measured after short term alteration in insulin therapy: * male or female with type 1 diabetes and intensified insulin therapy or insulin pump therapy. * signature of subjects to document consent with these procedures on informed consent form. exclusion criteria: * pregnancy or lactation period * severe acute disease (at the study physician's discretion) * severe chronic disease with potential risk during the test procedures (at the study physician's discretion) * current constitution that compromises the subject's capability to participate in the study (at the study physician's discretion) * being unable to give informed consent * \< 18 years * legally incompetent * being committed to an institution (e.g. psychiatric clinic) * language barriers potentially compromising an adequate compliance with study procedures * dependent on investigator or sponsor * if blood glucose values \< 80 mg/dl shall be measured after short term alteration in insulin therapy (concentration category 2, see fehler! verweisquelle konnte nicht gefunden werden.), subjects with type 1 diabetes, suffering from: * coronary heart disease * condition after myocardial infarction * condition after cerebral events * peripheral arterial occlusive disease * hypoglycemia unawareness